CAMP vs PRAX
CAMP: CAMP4 is pioneering a novel RNA-targeting platform to upregulate deficient genes in rare genetic diseases, starting with SYNGAP1-related developmental epilepsy. PRAX: A clinical-stage CNS biotech translating genetic epilepsy insights into precision therapies for neurological disorders via proprietary small-molecule and antisense oligonucleotide platforms.
Side-by-side fundamentals
| Metric | CAMP | PRAX | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $3.42 | $315.80 | |
| Market cap as of 2026-07-30 | $178M | $8.8B | |
| PEG as of 2026-07-30 | n/a | -0.89 | |
| Net margin as of 2026-07-30 | -7.3% | -2137.5% | CAMP higher |
| Gross margin as of 2026-07-30 | +35.8% | n/a | |
| Operating margin as of 2026-07-30 | -5.4% | -2340.3% | CAMP higher |
| ROE as of 2026-07-30 | -194.7% | -43.0% | PRAX higher |
| ROA as of 2026-07-30 | -95.6% | -40.2% | PRAX higher |
| Debt / equity as of 2026-07-30 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-30 | +5.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +216.1% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-30 | -22.58 | 2.82 | |
| 1-year return as of 2026-07-27 close | +89.0% | +433.3% | PRAX higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.